Hutchin Hill Capital’s Anika Therapeutics ANIK Stock Holding History

Hutchin Hill Capital’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$668K	Buy	12,400 +2,100	+20%	+$116K	0.19%	125
2017 Q3	$597K	Sell	10,300 -11,500	-53%	-$601K	0.02%	485
2017 Q2	$1.08M	Buy	+21,800	New	+$1M	0.04%	484
2015 Q4	–	Sell	-30,300	Closed	-$964K	–	623
2015 Q3	$964K	Buy	+30,300	New	+$1.06M	0.04%	417
2015 Q2	–	Sell	-34,900	Closed	-$1.44M	–	643
2015 Q1	$1.44M	Buy	+34,900	New	+$1.41M	0.04%	369
2014 Q4	–	Sell	-46,400	Closed	-$1.7M	–	546
2014 Q3	$1.7M	Buy	46,400 +14,800	+47%	+$640K	0.06%	268
2014 Q2	$1.46M	Sell	31,600 -9,000	-22%	-$400K	0.07%	248
2014 Q1	$1.67M	Sell	40,600 -1,700	-4%	-$63.2K	0.09%	252
2013 Q4	$1.61M	Buy	+42,300	New	+$1.31M	0.11%	192
2013 Q3	–	Sell	-12,400	Closed	-$211K	–	477
2013 Q2	$211K	Buy	+12,400	New	+$179K	0.02%	376

Other funds holding ANIK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AAM

AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

TAM

THB Asset Management Norwalk, Connecticut $440M AUM 59.59% 1-Year Est. Return

Hutchin Hill Capital's ANIK Position: Q4 2017 in Review

Hutchin Hill Capital increased its Anika Therapeutics (ANIK) stake by 20% in Q4 2017, buying an estimated $116K and bringing the position to 12,400 shares worth $668K. The position accounts for 0.19% of the portfolio, ranked #125.

Hutchin Hill Capital first reported a position in ANIK in Q2 2013 and has held it in 10 quarters since. The position peaked at $1.7M in Q3 2014. 172 funds tracked by Wall St. Rank hold ANIK as of Q4 2017.

Hutchin Hill Capital held 12,400 shares of Anika Therapeutics worth $668K as of Q4 2017.
Hutchin Hill Capital bought 2,100 Anika Therapeutics shares in Q4 2017, an estimated $116K.
Anika Therapeutics made up 0.19% of Hutchin Hill Capital's portfolio in Q4 2017, its #125 holding.
Hutchin Hill Capital first reported a position in Anika Therapeutics in Q2 2013 and has held it in 10 quarters since.
Hutchin Hill Capital's Anika Therapeutics position peaked at $1.7M in Q3 2014.
172 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2017.

Based on Hutchin Hill Capital's 13F filing for Q4 2017, filed 12 Feb 2018.